BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths.
Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.
Company Details
- Employees
- 20
- Founded
- 2008
- Address
- Jonas Lies Vei 91, Bergen,norway,norway
- ri****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bergenbio.com
- Keywords
- Drug discovery, Drug target discovery, Aggressive, drug-resistant cancer, AXL, oncology, acute myeloid leukaemia, Non-small cell lung cancer.
- HQ
- Bergen, Norway
Bergenbio Asa Questions
Bergenbio Asa's website is bergenbio.com
Bergenbio Asa's LinkedIn profile is https://no.linkedin.com/company/bergenbio-as
Bergenbio Asa has
20 employees.
View email and phone details for 20
employees at Bergenbio Asa.
Bergenbio Asa's industry is
Biotechnology Research
Bergenbio Asa's top competitors are
Lytix Biopharma,
Tempus Ai,
Ultimovacs Asa,
Cytovation,
Nykode Therapeutics,
Thor Medical Asa,
Algipharma As,
Zelluna,
Oncoinvent Asa,
Arctic Bioscience.
Bergenbio Asa's support email address is richard.godfrey@bergenbio.com
Bergenbio Asa's categories are Biotechnology Research
Bergenbio Asa's founding year is 2008
